239 related articles for article (PubMed ID: 32886422)
1. Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors.
Saleh RR; Meti N; Ribnikar D; Goldvaser H; Ocana A; Templeton AJ; Seruga B; Amir E
Cancer Med; 2020 Nov; 9(21):7888-7895. PubMed ID: 32886422
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade.
Ribnikar D; Goldvaser H; Veitch ZW; Ocana A; Templeton AJ; Šeruga B; Amir E
Sci Rep; 2021 May; 11(1):10843. PubMed ID: 34035370
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors.
Di Costanzo F; Napolitano F; Salomone F; Amato AR; Alberico G; Migliaccio F; Pecoraro G; Marra A; Crocetto F; Ruffo A; Scagliarini S; Rossetti S; Puglia L; Di Napoli M; Bianco R; Servetto A; Formisano L
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067406
[TBL] [Abstract][Full Text] [Related]
4. The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members.
Maillet D; Blay JY; You B; Rachdi A; Gan HK; Péron J
Ann Oncol; 2016 Jan; 27(1):192-8. PubMed ID: 26483049
[TBL] [Abstract][Full Text] [Related]
5. Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review.
Ter Veer E; van Kleef JJ; Sprangers MAG; Haj Mohammad N; van Oijen MGH; van Laarhoven HWM
Gastric Cancer; 2018 Mar; 21(2):183-195. PubMed ID: 29380191
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer.
Adamowicz K; Saad ED; Jassem J
Cancer Treat Rev; 2016 Nov; 50():194-199. PubMed ID: 27718458
[TBL] [Abstract][Full Text] [Related]
7. Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials.
Adamowicz K; Jassem J; Katz A; Saad ED
Cancer Treat Rev; 2012 Aug; 38(5):554-8. PubMed ID: 21807465
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review.
Patel K; Ivanov A; Jocelyn T; Hantel A; Garcia JS; Abel GA
JAMA Netw Open; 2024 Jun; 7(6):e2414425. PubMed ID: 38829615
[TBL] [Abstract][Full Text] [Related]
9. Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G).
Smith AB; Cocks K; Parry D; Taylor M
Qual Life Res; 2014 Apr; 23(3):971-6. PubMed ID: 24097080
[TBL] [Abstract][Full Text] [Related]
10. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses.
Ocana A; Ethier JL; Díez-González L; Corrales-Sánchez V; Srikanthan A; Gascón-Escribano MJ; Templeton AJ; Vera-Badillo F; Seruga B; Niraula S; Pandiella A; Amir E
Oncotarget; 2015 Nov; 6(37):39538-49. PubMed ID: 26446908
[TBL] [Abstract][Full Text] [Related]
11. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Novello S; Aglietta M; Scagliotti GV; Perrone F; Di Maio M
Ann Oncol; 2018 Dec; 29(12):2288-2295. PubMed ID: 30304498
[TBL] [Abstract][Full Text] [Related]
12. Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018.
Lombardi P; Marandino L; De Luca E; Zichi C; Reale ML; Pignataro D; Di Stefano RF; Ghisoni E; Mariniello A; Trevisi E; Leone G; Muratori L; La Salvia A; Sonetto C; Leone F; Aglietta M; Novello S; Scagliotti GV; Perrone F; Di Maio M
Crit Rev Oncol Hematol; 2020 Feb; 146():102877. PubMed ID: 31981880
[TBL] [Abstract][Full Text] [Related]
13. Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer.
Vera-Badillo FE; Shapiro R; Ocana A; Amir E; Tannock IF
Ann Oncol; 2013 May; 24(5):1238-44. PubMed ID: 23303339
[TBL] [Abstract][Full Text] [Related]
14. Reporting of Randomized Trials in Common Cancers in the Lay Media.
Ribnikar D; Goldvaser H; Ocana A; Templeton AJ; Seruga B; Amir E
Oncology; 2018; 94(2):65-71. PubMed ID: 29151109
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
[TBL] [Abstract][Full Text] [Related]
16. Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials.
Adamowicz K
Qual Life Res; 2017 Apr; 26(4):813-822. PubMed ID: 27738867
[TBL] [Abstract][Full Text] [Related]
17. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review.
Péron J; Maillet D; Gan HK; Chen EX; You B
J Clin Oncol; 2013 Nov; 31(31):3957-63. PubMed ID: 24062406
[TBL] [Abstract][Full Text] [Related]
18. Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review.
Komorowski AS; MacKay HJ; Pezo RC
Cancer Med; 2020 Jul; 9(14):5035-5050. PubMed ID: 32452660
[TBL] [Abstract][Full Text] [Related]
19. Assessment of quality of life in phase III trials of radiotherapy in localized or locally advanced head and neck cancer over the past 17 years.
Marta GN; Saad ED
Ann Palliat Med; 2017 Jan; 6(1):73-80. PubMed ID: 28209070
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies.
Voon PJ; Cella D; Hansen AR
Cancer; 2021 May; 127(9):1360-1368. PubMed ID: 33662145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
